China-Hospeq 2026: YHLO Brings Diagnostic Solutions to Global Health Partners


From August 14 to 16, 2026, the 32nd China-Hospeq was grandly held at the China National Convention Center in Beijing. Organized by the International Health Exchange and Cooperation Center of the National Health Commission of China, the event brought together over 300 exhibitors and attracted more than 25,000 professional visitors.

 

The exhibition focused on seven key areas, including advanced medical imaging, laboratory diagnostics, smart healthcare, and hospital construction, while hosting dozens of concurrent international conferences and policy seminars. 

 

It served as an important window into the localization and technological innovation of Chinese medical devices. As a representative player in the IVD industry, YHLO showcased its intelligent total laboratory automation systems and a range of core products at the exhibition.

YHLO presented its intelligent total laboratory automation systems, fully automated chemiluminescence immunoassay analyzers, and the Tenfly Phoenix fully automated immunoblot analyzer. The product display covered the diverse needs of large central laboratories as well as small-sized and medium-sized laboratories, precisely matching application scenarios across different scales. 

 

The simultaneous presentation of multiple products demonstrated YHLO's comprehensive product portfolio in laboratory automation and CLIA testing — from full-scenario coverage to flexible deployment — attracting many medical institution representatives and industry partners for in-depth discussions.

During the exhibition, the YHLO booth received multiple international delegations. On the opening day and the following day, representatives from Belt and Road countries, various African nations, and other developing countries – focusing on maternal and child health, cervical cancer screening, and related fields – visited the booth. 

The YHLO team provided systematic introductions to the features and clinical application scenarios of its products, offering live demonstrations of the full-process automation from sample loading to report output.

Subsequently, YHLO presented an analysis of the current status and challenges in reproductive health, infectious disease prevention and control, and maternal and child health in China and Belt and Road regions. Building on this, YHLO systematically introduced its test menus and total solutions in autoimmunity, cardiovascular diseases, reproductive health, and infectious diseases, as well as its global market presence and service capabilities. This helped visiting delegates gain a more intuitive and deeper understanding of the application value of YHLO's solutions. 

 

During the Q&A session that followed, delegates engaged in lively discussions with the YHLO team on topics such as equipment throughput, reagent menus, local adaptation, and after-sales support, with many expressing strong interest in the potential application of these technologies in their home countries.

In addition to international delegations, representatives from the National Health Commissions of several Chinese provinces also visited the YHLO booth. Ms. Yu Qiuping, Director of YHLO's Global Market Technical Center, provided a comprehensive overview of the company's development history, core product portfolio, and overall capabilities, highlighting innovations and industrialization achievements in smart laboratory construction, autoimmunity, cardiovascular diseases, diabetes, and infectious disease prevention and control. 

 

The visiting representatives expressed high interest and positive recognition of YHLO's efforts in promoting domestic substitution of IVD products and strengthening primary healthcare capacity.

This successful participation in China-Hospeq 2026 marks a significant step in YHLO’s continued commitment to the domestic market and the high-quality development of laboratory medicine. On the path of going global, YHLO is not only dedicated to "selling products abroad" but also to "building local capabilities." 

 

Today, YHLO products are available in over 120 countries and regions, with service coverage spanning Europe, the CIS, the Middle East, Africa, Latin America, and the Asia-Pacific. Most of these countries lie along the Belt and Road – from North Africa to the Middle East, from West Asia to South Asia – forming a support chain underpinned by localized services. Equipment training, routine maintenance, and clinical application guidance can now reach users with shorter distances and faster response times, enabling "YHLO diagnostics" to truly take root and stand firm overseas.

Going forward, YHLO remains committed to its mission, “Focus on healthcare, better life with technology,” while resolutely pushing forward its globalization efforts.YHLO will further strengthen its overseas service network, drive healthcare transformation with innovative products and research, and support medical capacity building in partner countries – contributing to better health outcomes worldwide.

Attachments:


MORE NEWS


China-Hospeq 2026: YHLO Brings Diagnostic Solutions to Global Health Partners


YHLO Brings Diagnostic Solutions to Global Health Partners at China-Hospeq 2026

2026-08-20

ADLM 2026: YHLO Brings Proven Lab Automation to the Americas


YHLO showcases its innovative products and academic achievements at ADLM 2026.

2026-08-01